Receive a summary of latest published content every two weeks.
Liposomal Irinotecan Fails To Extend Advanced SCLC Survival
From ELCC 2023:
Liposomal irinotecan does not offer significantly better overall survival than topotecan for patients with small-cell lung cancer that has progressed during or after first-line platinum-based chemotherapy